13F Holdings
中文EN

ABVC ABVC BIOPHARMA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1173313 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY234.3%
TTM net income YoY62.5%
TTM EPS YoY76.7%
Revenue 3-yr CAGR12.7%
Net income 3-yr CAGR—

Margins

Gross margin99.9%
Operating margin-850.7%
Net margin-773.6%
FCF margin—
EBITDA margin-840.1%

Returns

ROE-283.6%
ROA-51.4%
ROIC (approx.)-570.9%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets90.4%
Debt / equity0.00x
Current ratio0.33x
Interest coverage-5.25x

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———-$499,950$795,950——$1,966
Cost of revenue———————$0
Gross profit————$795,950——$1,966
R&D expense$18,040$22,707$33,100$29,058$29,890$33,276$28,861$31,980
SG&A expense$376,946$503,778$751,998$783,640$798,253$690,094$615,371$488,420
Operating income-$1.24M-$779,526-$1.57M-$2.99M-$1.96M-$2.29M-$693,005-$334,158
Interest expense$43,649$42,323$49,377$32,551$30,959$129,413$222,967$216,715
Pretax income-$1.39M-$810,481-$1.69M-$3.81M-$2.08M-$2.31M-$944,190$128,943
Income tax———$0$527$23,627—$0
Net income$1.15M-$736,934-$1.56M-$3.56M-$2.04M-$2.26M-$842,075$229,304
EBITDA-$1.23M-$767,227-$1.57M-$2.99M-$1.94M-$2.28M-$685,984-$323,738
EPS (basic)0.04-0.03-0.06—-0.09-0.13-0.06—
EPS (diluted)0.04-0.03-0.06—-0.09-0.13-0.06—
Weighted avg. shares (diluted)26.66M26.06M25.45M—23.26M17.39M14.97M—
Balance sheet
Cash & equivalents$11,294$31,944$140,324$681,480$192,068$1.08M$759,568$863,815
Short-term investments$55,160$62,420$62,185$64,354$65,175$65,211$65,052$64,736
Inventory————$11,460$11,460$11,460—
Current assets$1.40M$411,729$648,848$3.26M$3.31M$2.77M$1.47M$2.18M
PP&E, net$12.83M$12.83M$12.82M$12.84M$12.85M$8.22M$8.17M$511,088
Total assets$20.30M$19.40M$19.73M$21.82M$21.21M$16.24M$14.88M$7.54M
Current liabilities$7.19M$5.69M$5.39M$6.92M$6.54M$6.53M$6.73M$6.56M
Short-term debt$30,000$59,462$88,737$755,512$809,103$871,951$801,407$840,252
Total liabilities$8.55M$7.13M$6.90M$8.52M$6.72M$6.75M$6.92M$6.82M
Shareholders' equity$13.05M$10.29M$10.77M$11.11M$12.06M$7.01M$5.40M$1.23M
Shares outstanding26.84M25.77M25.77M25.05M24.19M19.53M15.38M13.87M
Cash flow statement
Operating cash flow-$438,911-$244,413-$894,243-$1.42M-$133,257-$894,174-$539,833-$493,611
Investing cash flow-$23,498-$101,531$47,123$730,346-$1.27M———
Financing cash flow$408,697$226,209-$342,181$1.15M$1.13M$1.93M$428,756$581,456
Depreciation & amortization$6,906$12,299$5,783$5,791$25,330$13,718$7,021$10,420
Stock-based compensation$845,607$253,041$787,374$1.39M$1.14M$1.57M$48,773$363,079

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.